weight loss information com

Sibutramine, Weight Loss and Resting Metabolic Rate (RMR)
Meridia / Sibutramine Does Not Directly Affect Basal Metabolic Rate
Weight Loss Diet Advice - Weight Reduction Advice

Questions About Obesity Medications
Appetite Suppressants - Anti-Obesity Drugs - Prescription Obesity Drugs
Development of Diet Pills - Meridia Short-Term Obesity Drug - Xenical Lipase Inhibitors - Xenical Study
Orlistat & Obesity Management - Orlistat Weight Loss Study - Sibutramine FDA Approved Obesity Drug
Sibutramine Study - Obesity Drugs & Diabetes - Risks of Weight Loss Pills - Adipex Obesity Drug
Side Effects of Adipex - Phentermine to Reduce Appetite - Side Effects of Phentermine

Sibutramine Effects on Resting Metabolic Rate (RMR) and Weight Loss

Sibutramine, a monoamine re-uptake inhibitor, has recently been approved by the Food and Drug Administration as a weight loss agent. Sibutramine lowers bodyweight in rodents by reducing energy intake and increasing energy expenditure. Sibutramine facilitates weight loss in human subjects, but it is not clear whether it acts on energy intake, energy expenditure, or both. The present study was a randomized clinical trial designed to assess the effects of sibutramine (at 10 or 30 mg/day) on body weight and resting metabolic rate (RMR). Forty-four overweight women were randomized to 1) placebo; 2) sibutramine at 10 mg/day or, 3) sibutramine at 30 mg/day. All subjects were instructed to consume a 1200 kcal/day diet for 8 weeks while receiving drug or placebo. RMR was assessed by indirect calorimetry at baseline, at 3 hours after the first dose of drug (or placebo), and at the end of the 8-week weight-loss period.

In summary, while sibutramine was shown to be an effective weight-loss agent over 8 weeks, we found no evidence that it increased RMR.

Source: Seagle HM, Bessesen DH, Hill JO. Department of Pediatrics, Center for Human Nutrition, University of Colorado Health Sciences Center, Denver 80262, USA. 1998

Return to Weight Loss Research Articles